Novel Aptamer-Nanoparticle Bioconjugates Enhances Delivery of Anticancer Drug to MUC1-Positive Cancer Cells In Vitro
Figure 3
Analysis of aptamer conjugation to microparticles or nanoparticles.
The PLGA microparticles (MPs) or nanoparticles (NPs) reacted with aptamers in the absence (-EDC&NHS) or presence (+EDC&NHS) of the catalysts. (A) Histograms of FCM analysis of MP reacted with FITC-labeled aptamers in the absence (-EDC&NHS, left) or presence (+EDC&NHS, right) of the catalysts. Plain microparticles that had not reacted with aptamers were used as control. (B) UV absorption of DNA at 260 nm (n = 3) on the particles that underwent conjugation process with aptamers. The control group (NPs) indicates plain nanoparticles that have not reacted with DNA aptamers.